Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only

Bone Metastases in Subjects With Advanced Breast Cancer Clinical Trial

Official title: An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab in the Treatment of Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma

Status Completed

Clinical Trial Summary

The purpose of this study is to describe the safety and tolerability of denosumab administration as measured by adverse events, immunogenicity, and safety laboratory parameters in subjects who previously received either zoledronic acid (Zometa®) or denosumab.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Related Conditions & MeSH terms

• Bone Marrow Diseases
• Bone Metastases in Men With Hormone-Refractory Prostate Cancer
• Bone Metastases in Subjects With Advanced Breast Cancer
• Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
• Bone Neoplasms
• Breast Neoplasms
• Multiple Myeloma
• Neoplasm Metastasis
• Neoplasms
• Neoplasms, Plasma Cell
• Neoplasms, Second Primary
• Prostatic Neoplasms

• NCT number: NCT00950911
• Study type: Interventional
• Source: Amgen
• Status: Completed
• Phase: Phase 3
• Start date: July 2009
• Completion date: April 2012